Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Revolution Medicines

DB:42Z
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
42Z
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Revolution Medicines has significant price volatility in the past 3 months.
42Z Share Price and Events
7 Day Returns
12.3%
DB:42Z
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:42Z
-7.4%
DE Biotechs
-14.2%
DE Market
42Z Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Revolution Medicines (42Z) 12.3% -22.2% - - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 42Z.
  • No trading data on 42Z.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

42Z Value

 Is Revolution Medicines undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Revolution Medicines is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Revolution Medicines has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Revolution Medicines. This is due to cash flow or dividend data being unavailable. The share price is €21.6.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Revolution Medicines's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Revolution Medicines's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:42Z PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-22.33
NasdaqGS:RVMD Share Price ** NasdaqGS (2020-04-08) in USD $23.36
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Revolution Medicines.

DB:42Z PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RVMD Share Price ÷ EPS (both in USD)

= 23.36 ÷ -22.33

-1.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revolution Medicines is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Revolution Medicines is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Revolution Medicines's expected growth come at a high price?
Raw Data
DB:42Z PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
21.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Revolution Medicines, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Revolution Medicines's assets?
Raw Data
DB:42Z PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-46.35
NasdaqGS:RVMD Share Price * NasdaqGS (2020-04-08) in USD $23.36
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:42Z PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RVMD Share Price ÷ Book Value per Share (both in USD)

= 23.36 ÷ -46.35

-0.5x

* Primary Listing of Revolution Medicines.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revolution Medicines has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Revolution Medicines's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Revolution Medicines's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Revolution Medicines's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Revolution Medicines has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

42Z Future Performance

 How is Revolution Medicines expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Revolution Medicines expected to grow at an attractive rate?
  • Revolution Medicines's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Revolution Medicines's earnings growth is expected to exceed the Germany market average.
  • Revolution Medicines's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:42Z Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:42Z Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 21.7%
DB:42Z Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts -3.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:42Z Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:42Z Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 56 1 9 1
2023-12-31 15 -3 -29 1
2022-12-31 57 -45 -74 3
2021-12-31 47 -88 -97 4
2020-12-31 57 -86 -91 4
2020-04-08
DB:42Z Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 50 -50 -62
2019-09-30 48 -50 -57
2018-12-31 20 1 -49
2017-12-31 -25 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Revolution Medicines's earnings are expected to grow significantly at over 20% yearly.
  • Revolution Medicines's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:42Z Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Revolution Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:42Z Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.25 1.40 -0.91 2.00
2023-12-31 -0.35 0.68 -1.38 2.00
2022-12-31 -1.15 -0.91 -1.58 3.00
2021-12-31 -1.55 -1.08 -1.96 4.00
2020-12-31 -1.55 -1.37 -1.72 4.00
2020-04-08
DB:42Z Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -22.33
2019-09-30 -21.25
2018-12-31 -21.24
2017-12-31 -20.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Revolution Medicines will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Revolution Medicines's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Revolution Medicines has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

42Z Past Performance

  How has Revolution Medicines performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Revolution Medicines's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Revolution Medicines does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Revolution Medicines's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Revolution Medicines's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Revolution Medicines's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Revolution Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:42Z Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 50.04 -61.90 12.41
2019-09-30 48.30 -56.91 11.03
2018-12-31 20.17 -48.82 9.01
2017-12-31 -34.89 4.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Revolution Medicines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Revolution Medicines has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Revolution Medicines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Revolution Medicines's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Revolution Medicines has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

42Z Health

 How is Revolution Medicines's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Revolution Medicines's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Revolution Medicines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Revolution Medicines's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Revolution Medicines's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Revolution Medicines has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Revolution Medicines Company Filings, last reported 3 months ago.

DB:42Z Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 152.54 0.00 122.76
2019-09-30 165.67 0.00 136.29
2018-12-31 96.66 0.00 69.59
2017-12-31 4.53 0.00 9.08
  • Revolution Medicines has no debt.
  • Revolution Medicines has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Revolution Medicines has sufficient cash runway for 2.7 years based on current free cash flow.
  • Revolution Medicines has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 43.9% each year.
X
Financial health checks
We assess Revolution Medicines's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Revolution Medicines has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

42Z Dividends

 What is Revolution Medicines's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Revolution Medicines dividends.
If you bought €2,000 of Revolution Medicines shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Revolution Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Revolution Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:42Z Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:42Z Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Revolution Medicines has not reported any payouts.
  • Unable to verify if Revolution Medicines's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Revolution Medicines's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Revolution Medicines has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Revolution Medicines's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Revolution Medicines afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Revolution Medicines has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

42Z Management

 What is the CEO of Revolution Medicines's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Goldsmith
COMPENSATION $4,315,274
AGE 57
TENURE AS CEO 5.4 years
CEO Bio

Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Partner at Third Rock Ventures, LLC since joining in 2012. Previously, he was a Partner at Third Rock Ventures since 2013. Dr. Goldsmith served as an Interim Chief Executive Officer of Nurix, Inc. Dr. Goldsmith served as the Interim Chief Executive Officer of Global Blood Therapeutics, Inc until June 2014. Dr. Goldsmith was a Venture Partner. Dr. Goldsmith served as an Assistant Director of the Gladstone Institute of Virology and Immunology of J. David Gladstone Institutes. He held senior executive positions in the biotechnology industry and academia. He led the development of an industry-leading strategic alliance with Genentech and remains active as its Chairman. Prior to his appointment at Constellation in 2009, he served as a Senior Executive-in-Residence at Prospect Venture Partners. He co-founded Cogentus Pharmaceuticals, Inc. and served as its Chairman, Chief Executive Officer and President. Dr. Goldsmith served as a Senior Vice President of Health Care at Danisco US Inc. since June 18, 2003. He has consulted extensively in the biotechnology and pharmaceutical industries. Dr. Goldsmith joined Genencor in 2001 from the faculty of the University of California at San Francisco (UCSF) and the Gladstone Institute of Virology and Immunology, where he was a distinguished physician-scientist who led a major research program in the areas of immunologic and virologic diseases. Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the University of California, San Francisco School of Medicine and at San Francisco General Hospital and was a Consultant to leading pharmaceutical and biotechnology companies. He practiced medicine on the faculty of the University of California, San Francisco School of Medicine and at San Francisco General Hospital. He serves as the Chairman of the Board at Constellation Pharmaceuticals, Inc., where he served as the Chief Executive Officer since August 2009 and served as its President. He served as the Chairman of the Board at Nurix, Inc since September 2014 until May 3, 2016. Dr. Goldsmith serves as Director at Igenica, Inc. He served as a Director of Global Blood Therapeutics, Inc. until September 2014. He served as a Director of Cogentus Pharmaceuticals, Inc. He has many years of experience in the life sciences. He plays an instrumental role in the ideation, development and leadership of new companies. Dr. Goldsmith received his A.B. in biology from Princeton University and conducted postgraduate medical training in Medical Science at Harvard Medical School and the University of California, San Francisco. He earned his M.D. and Ph.D. in Microbiology and Immunology from the University of California, San Francisco.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Revolution Medicines management team in years:

3.2
Average Tenure
56
Average Age
  • The tenure for the Revolution Medicines management team is about average.
Management Team

Mark Goldsmith

TITLE
CEO, President & Chairman
COMPENSATION
$4M
AGE
57
TENURE
5.4 yrs

Peg Horn

TITLE
COO & General Counsel
COMPENSATION
$2M
AGE
56
TENURE
1.5 yrs

Steve Kelsey

TITLE
President of Research & Development
COMPENSATION
$2M
AGE
58
TENURE
3.1 yrs

Marty Burke

TITLE
Co-Founder & Chairman of Scientific Advisory Board

Michael Fischbach

TITLE
Academic Co-Founder & Member of Scientific Advisory Board
AGE
38

Kevan Shokat

TITLE
Academic Co-Founder & Member of Scientific Advisory Board
TENURE
3.3 yrs

Jack Anders

TITLE
VP of Finance & Principal Accounting Officer
AGE
42
TENURE
1.7 yrs

David Pompliano

TITLE
Founding Chief Scientific Officer

Luan Wilfong

TITLE
Senior Vice President of Human Resources
TENURE
5.1 yrs

Xiaolin Wang

TITLE
Senior Vice President of Clinical Development
Board of Directors Tenure

Average tenure and age of the Revolution Medicines board of directors in years:

3.3
Average Tenure
61
Average Age
  • The tenure for the Revolution Medicines board of directors is about average.
Board of Directors

Marty Burke

TITLE
Co-Founder & Chairman of Scientific Advisory Board

Michael Fischbach

TITLE
Academic Co-Founder & Member of Scientific Advisory Board
AGE
38
TENURE
3.8 yrs

Kevan Shokat

TITLE
Academic Co-Founder & Member of Scientific Advisory Board
TENURE
3.3 yrs

Alexis Borisy

TITLE
Lead Independent Director
COMPENSATION
$343K
AGE
47

Mark Goldsmith

TITLE
CEO, President & Chairman
COMPENSATION
$4M
AGE
57

Liz Anderson

TITLE
Independent Director
COMPENSATION
$132K
AGE
62
TENURE
5.1 yrs

Barbara Weber

TITLE
Independent Director
COMPENSATION
$175K
AGE
62
TENURE
2 yrs

Neil Exter

TITLE
Independent Director
AGE
61
TENURE
0.8 yrs

Eric Gordon

TITLE
Senior Advisor & Member of Scientific Advisory Board
TENURE
3.8 yrs

Julian Adams

TITLE
Senior Advisor & Member of Scientific Advisory Board
AGE
64
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Feb 20 Buy Deerfield Management Company, L.P. Company 18. Feb 20 18. Feb 20 600,000 €15.71 €9,428,880
X
Management checks
We assess Revolution Medicines's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Revolution Medicines has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

42Z News

Simply Wall St News

42Z Company Info

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company’s principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.

Details
Name: Revolution Medicines, Inc.
42Z
Exchange: DB
Founded: 2014
$1,267,448,472
59,000,883
Website: http://www.revmed.com
Address: Revolution Medicines, Inc.
700 Saginaw Drive,
Redwood City,
California, 94063,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RVMD Common Stock Nasdaq Global Select US USD 13. Feb 2020
DB 42Z Common Stock Deutsche Boerse AG DE EUR 13. Feb 2020
BST 42Z Common Stock Boerse-Stuttgart DE EUR 13. Feb 2020
Number of employees
Current staff
Staff numbers
95
Revolution Medicines employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:27
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.